Soleno Therapeutics (SLNO) surges 33%+ premarket on Neurocrine’s $2.9B all-cash bid — April 6, 2026

NEW YORK, April 6, 2026 — Soleno Therapeutics, Inc. (NASDAQ: SLNO) posted the largest premarket percentage gain among major U.S. equities on Monday morning, with shares surging more than 33% to approximately $52.46 after Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced a definitive agreement to acquire the Redwood City, California-based biopharmaceutical company for $53.00 per share in cash, representing a total transaction equity value of approximately $2.9 billion.

The premarket move catapulted SLNO from its prior close of $39.49 to within striking distance of the all-cash offer price, with total day-session volume reaching 33.56 million shares — compared to an average daily volume of approximately 2.06 million shares — reflecting more than a sixteenfold surge in activity as investors crowded into merger arbitrage positions. The catalyst was unambiguous: Neurocrine’s offer delivers a 34% premium to Soleno’s April 2, 2026 closing price and a 51% premium to its 30-day volume-weighted average price, according to the official transaction terms filed with regulators. Trading in SLNO was briefly halted pre-market for a news-pending designation, consistent with a planned announcement, before reopening sharply higher once the definitive agreement was confirmed.

The acquisition centres on VYKAT XR (diazoxide choline extended-release), Soleno’s sole commercial product and the first and only therapy approved by the U.S. Food and Drug Administration to treat hyperphagia — a condition of relentless, compulsive hunger — in patients with Prader-Willi syndrome (PWS), a rare genetic disorder affecting roughly 10,000 people in the United States. VYKAT XR received FDA approval in the second quarter of 2025 and generated $190 million in revenue in its first year on the market, including $92 million in the fourth quarter of 2025 alone, demonstrating rapid commercial uptake in a highly specialised patient population. The deal catapulted the Neurocrine-Soleno story to the top of premarket trading boards across platforms, including CNBC’s premarket movers list and Bloomberg’s deal coverage.

Neurocrine’s $2.9B acquisition of Soleno — the full picture

The merger agreement, signed on April 5, 2026, was first reported by the Financial Times on Sunday evening, sending SLNO shares more than 20% higher in overnight trading before the official announcement lifted the gain further. Neurocrine Biosciences and Soleno Therapeutics formally announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion.

The acquisition of Soleno and the addition of VYKAT XR (diazoxide choline), a first-in-class therapy to treat hyperphagia, the defining feature of Prader-Willi syndrome, will expand Neurocrine’s portfolio of innovative medicines and strengthen its leadership position in endocrinology and rare disease.

Under the terms of the merger agreement, Neurocrine will commence a cash tender offer to acquire all outstanding shares of Soleno’s common stock at a price of $53.00 per share, representing a premium of approximately 34% to Soleno’s closing share price on April 2, 2026, and a premium of 51% to Soleno’s 30-day volume-weighted average price. Soleno’s board unanimously approved the transaction and recommends that stockholders tender their shares.

Both company boards have approved the transaction, which is expected to close within 90 days. The transaction will be funded with cash on hand, but Neurocrine said it plans to take on some new debt. The merger agreement includes termination fees of $95.25 million payable by Soleno in certain cases and $141.5 million payable by Neurocrine if antitrust approval is not obtained.

For Neurocrine, the strategic imperative is clear. The deal would give Neurocrine its first metabolic disease drug — something that has evolved from a “nice to have” to a “must have” in the GLP-1 era. Following completion, Neurocrine will have three marketed, first-in-class therapies: INGREZZA, the VMAT2 market leader for the treatment of tardive dyskinesia and Huntington’s disease chorea, with $2.51 billion in 2025 revenue; CRENESSITY, approved in December 2024 for classic congenital adrenal hyperplasia, with $301 million in 2025 revenue; and VYKAT XR, with $190 million in 2025 revenue for Soleno.

What the numbers say

SLNO’s most recent financial results

Soleno Therapeutics last posted quarterly earnings data on February 25, 2026. The company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to analysts’ expectations of $88.55 million. VYKAT XR’s commercial trajectory — generating $92 million in Q4 2025 alone — was the central commercial proof point that made Soleno an acquisition target, validating the biotech’s multi-year development narrative.

Volume and price action

The stock had previously closed at $39.49 but opened at $52.31. Soleno Therapeutics shares last traded at $52.1850, with a volume of 33,562,619 shares changing hands. Trading activity reflected a volume of 3.57 million shares in earlier premarket data alone, compared to an average daily volume of 2.06 million. Over the past 52 weeks, SLNO had traded between a high of $90.32 and a low of $29.43. The deal price of $53 thus represents a recovery of most of that 52-week range in a single session, reflecting the completeness of the acquisition premium.

Analyst reactions

Wall Street commentary was broadly constructive for Neurocrine and unambiguous for Soleno shareholders. For Neurocrine, swallowing Soleno “makes very reasonable strategic sense,” analysts at RBC Capital Markets wrote to investors on Monday. Oppenheimer subsequently raised the firm’s price target on Neurocrine to $220 from $192 and kept an Outperform rating on the shares. UBS reiterated a Buy rating and $161.00 price target on Neurocrine Biosciences as the company completed its acquisition of Soleno Therapeutics.

Despite the premium offered by Neurocrine, analysts at Stifel found the acquisition “surprising” from Soleno’s perspective, writing to investors on Monday that they were “admittedly surprised SLNO sold at this price,” adding that they remained bullish on the launch of VYKAT XR, which was approved in March 2025 to treat extreme hunger in patients with Prader-Willi syndrome.

The deal would offer a “more sensible way into metabolic disease” than Neurocrine’s own obesity candidates still in preclinical testing, given competitive and regulatory hurdles, BMO Capital Markets analyst Evan Seigerman said in a note. BMO Capital Markets forecasted $450 million in sales for VYKAT XR in 2026, projecting that it could hit over $2 billion worldwide by the mid-2030s.

Expected intellectual property protection for VYKAT XR extends into the mid-2040s. Oppenheimer added VYKAT XR to its model with estimated sales of approximately $270 million for the second half of 2026 post-close, reaching over $2.3 billion at peak.

The broader biotech deal landscape provided useful context. The deal is the latest in a busy year for dealmaking in the biotech industry. In the first quarter, biotechs and pharmaceutical companies inked $68.6 billion in deals, according to data provider LSEG. More detail on the deal and its sector implications can be found in the PreMarket Daily opening bell report for April 6, 2026.

Sector context and what to watch at the open

The SLNO surge dominated premarket activity in the healthcare sector on Monday, but it did not operate in isolation from broader market themes. U.S. stock index futures inched higher on Monday, after the main indexes marked their biggest weekly jump in four months in the last session, as investors assessed prospects of an end to the Middle East conflict. Trading volumes remained thin as several global markets were closed for Easter Monday, leading to a cautious, defensive posture among domestic traders throughout the morning session.

Within the healthcare sector specifically, the SLNO-NBIX deal drew attention to the competitive landscape in Prader-Willi syndrome treatment. Rhythm Pharmaceuticals (NASDAQ: RYTM), which is currently initiating a Phase 3 registrational trial for setmelanotide in PWS, now faces a competitor with much deeper pockets and an established sales force. Acadia Pharmaceuticals was forced to discontinue its own PWS program, ACP-101, in September 2025 after a failed Phase 3 trial, a failure that effectively cleared the runway for Soleno’s market dominance. Other players, like Aardvark Therapeutics, have also faced setbacks, including a voluntary pause of their Phase 3 HERO trial in February 2026 due to safety concerns, further entrenching Soleno’s lead.

For NBIX, shares fell approximately 2–3% in premarket, a common reaction for acquiring companies in all-cash deals. Neurocrine Biosciences shares were down 2.74% at $128.00 during premarket trading on Monday, while Soleno Therapeutics shares were up 32.84% at $52.46. The key price level for SLNO at the open was the $53.00 deal price itself; any sustained trading materially below that figure would indicate merger arbitrage discount widening due to perceived regulatory or closing risk. Conversely, trading at or near $52.80–$53.00 would signal high market confidence in deal completion. Investors should also monitor any updated guidance from the Hart-Scott-Rodino antitrust review process, which could affect the expected 90-day closing timeline. Context on broader sector movements and the week’s catalysts is available in the PreMarket Daily Week Ahead briefing for April 6, 2026, and in the site’s ongoing pre-market briefing covering oil, Iran’s deadline, and futures signalling.

The broader rare-disease M&A backdrop also warrants attention. The Neurocrine-Soleno deal is emblematic of a broader trend in the 2026 biotech market — the aggressive acquisition of de-risked rare disease assets. As large-cap pharmaceutical companies face a patent cliff between 2026 and 2030, they are increasingly willing to pay high premiums for companies that have already secured FDA approval and demonstrated early commercial traction. The sustainability of that trend will be determined in part by whether regulators move to scrutinise rare-disease pricing and consolidation more aggressively in the quarters ahead.

Forward assessment

For SLNO shareholders, the $53.00 per-share all-cash offer provides a definitive and near-certain outcome, subject to standard regulatory and shareholder conditions. The merger arbitrage spread — the gap between the premarket price of approximately $52.46 and the deal price of $53.00 — implied a modest annualised return for risk arbitrageurs betting on completion within the 90-day window, consistent with a deal the market regards as low-risk from an antitrust perspective. As the only approved treatment addressing hyperphagia in PWS, VYKAT XR is a primary therapy option, supported by intellectual property protections extending into the 2040s. That competitive moat substantially reduces the probability of a regulatory challenge on public-interest grounds, though the HSR waiting-period process remains a procedural requirement. For Neurocrine, the more consequential variable is commercial execution: BMO Capital Markets projected $450 million in VYKAT XR sales in 2026, and noted that “acceleration of the commercial launch and penetration will be critical for Neurocrine to drive ROI of the asset and acquisition.” The acquirer’s established endocrinology sales infrastructure and three-product rare-disease portfolio provide a plausible basis for that acceleration, though VYKAT XR’s relatively narrow approved indication — hyperphagia in PWS patients — caps near-term peak-sales assumptions absent label expansions. The April 6 session thus sets a clear reference point for the NBIX-SLNO relationship: a high-confidence deal at a strong premium, with execution optionality concentrated on the Neurocrine side. How rapidly the company ramps VYKAT XR beyond $190 million in annual revenue will define whether the $2.9 billion price tag proves visionary or merely fair.